menu
    • menu

    Company profile for Alebund Pharmaceuticals

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Alebund is a clinical stage biopharmaceutical company focusing on novel therapies discovery and development primarily for kidney diseases and their complications, as well as other chronic conditions. Alebund was founded in Shanghai in early 2018, as a startup jointly incubated by a group of industry leaders in the field of nephrology and Lilly Asia Ventures. Supported by numerous renowned institutional investors specialized in...
    Alebund is a clinical stage biopharmaceutical company focusing on novel therapies discovery and development primarily for kidney diseases and their complications, as well as other chronic conditions. Alebund was founded in Shanghai in early 2018, as a startup jointly incubated by a group of industry leaders in the field of nephrology and Lilly Asia Ventures. Supported by numerous renowned institutional investors specialized in the biopharmaceutical industry, Alebund has built a diversified and balanced pipeline of drug candidates targeting a range of renal diseases, including chronic kidney disease (CKD)/dialysis complications.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Alebund PharmaceuticalsChina Flag
    Country
    Country
    China
    Address
    Address
    1206 Hong Kong Plaza South Tower, 283 Central Huaihai Road
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.alebund.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alebund Unveils AP301 Phase 3 Trial Results at ASN 2025 Congress
    Alebund Unveils AP301 Phase 3 Trial Results at ASN 2025 Congress

    07 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/alebund-presents-phase-3-trial-results-of-ap301-at-the-american-society-of-nephrology-asn-2025-congress-302605683.html

    PR NEWSWIRE
    07 Nov 2025
    Share Share
    Alebund Reports Positive Ph 3 Results for AP301
    Alebund Reports Positive Ph 3 Results for AP301

    26 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/alebund-announces-positive-topline-results-from-pivotal-phase-3-study-of-ap301-for-serum-phosphorus-control-in-dialysis-patients-with-hyperphosphatemia-302490399.html

    PR NEWSWIRE
    26 Jun 2025
    Share Share
    Alebund Closes RMB 550M In Series C Financing Round
    Alebund Closes RMB 550M In Series C Financing Round

    07 Jan 2025

    // #N/A

    https://www.prnewswire.com/news-releases/alebund-pharmaceutical-announced-the-1st-closing-of-rmb-550-million-in-series-c-financing-302342508.html

    #N/A
    07 Jan 2025
    Share Share
    Alebund's Investigational Drug AP303 Receives FDA ODD for the Treatment of ADPKD
    Alebund's Investigational Drug AP303 Receives FDA ODD for the Treatment of ADPKD

    29 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/alebunds-innovative-investigational-drug-ap303-receives-fda-orphan-drug-designation-odd-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd-302101896.html

    PR NEWSWIRE
    29 Mar 2024
    Share Share
    Alebund Reports Update for AP306 (EOS789)
    Alebund Reports Update for AP306 (EOS789)

    13 Dec 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/alebund-reports-update-for-ap306-eos789-a-first-in-class-pan-inhibitor-of-sodium-dependent-phosphate-transporters-from-a-completed-phase-ii-clinical-trial-in-patients-with-hyperphosphatemia-on-hemodialysis-302013538.html

    PR NEWSWIRE
    13 Dec 2023
    Share Share
    LAV’s Xia parlays gap in kidney therapies into China start-up
    LAV’s Xia parlays gap in kidney therapies into China start-up

    12 Oct 2021

    // Jaff Cranmer BIOCENTURY

    https://www.biocentury.com/article/640122/lav-s-xia-parlays-gap-in-kidney-therapies-into-china-start-up

    Jaff Cranmer BIOCENTURY
    12 Oct 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search